BlackRock Amends Atara Bio Stake, Signals Portfolio Adjustment
Ticker: ATRA · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment, biotechnology
TL;DR
**BlackRock updated its Atara Bio stake, signaling a portfolio rebalance.**
AI Summary
BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating a change in its ownership of Atara Biotherapeutics, Inc. common stock as of December 31, 2023. This amendment, number 7, updates their previous disclosures regarding their passive investment in the biotechnology company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal shifts in their confidence or investment strategy regarding Atara Biotherapeutics, potentially influencing other investors.
Why It Matters
Changes in major institutional holdings like BlackRock's can influence market perception and stock price, as they often reflect a professional assessment of the company's future prospects.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate, significant risk to the company or its stock.
Analyst Insight
Investors should monitor the full SC 13G/A filing for specific changes in BlackRock's ownership percentage and share count to understand the magnitude of their portfolio adjustment in Atara Biotherapeutics, Inc. and assess potential market impact.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Atara Biotherapeutics, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
- 046513107 (number) — the CUSIP number for Atara Biotherapeutics, Inc. Common Stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'Amendment No: 7' sections.
Who is the subject company of this filing?
The subject company is Atara Biotherapeutics, Inc., as indicated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc.'
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'
What was the date of the event that triggered this filing?
The date of the event which requires the filing of this statement was December 31, 2023, as specified in the filing.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Atara Biotherapeutics, Inc. is 046513107, as listed in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding Atara Biotherapeutics, Inc. (ATRA).